1. Scrip

Flamel buys Éclat and takes CEO for its own

 
• By Sukaina Virji

Flamel Technologies, a French drug delivery company, has acquired Éclat Pharmaceuticals of the US, a specialty pharmaceutical company focused on niche brands and generic products. Prior to the acquisition, Éclat was an affiliate of Deerfield Capital, which is Flamel's largest shareholder.

Flamel Technologies, a French drug delivery company, has acquired Éclat Pharmaceuticals of the US, a specialty pharmaceutical company focused on niche brands and generic products. Prior to the acquisition, Éclat was an affiliate of Deerfield Capital, which is Flamel's largest shareholder.

Under the deal, Éclat's founder and chief executive officer Mike Anderson is taking over as CEO of Flamel. The current...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial